Glycaemic, cardiorenal, and lipid parameters associated with SGLT2 inhibitors use in Indonesian patients with type 2 diabetes: 12-month multicenter real-world study
Fonny Cokro, Rani Sauriasari, Dicky Levenus Tahapary, Heri Setiawan, Christian Tricaesario, Nurul Hidayati, William Djauhari, Jimmy Tandradynata · 2026
Read Glycaemic, cardiorenal, and lipid parameters associated with SGLT2 inhibitors use in Indonesian patients with type 2 diabetes: 12-month multicenter real-world study by Fonny Cokro, Rani Sauriasari, Dicky Levenus Tahapary, Heri Setiawan, Christian Tricaesario, Nurul Hidayati, William Djauhari, Jimmy Tandradynata (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0353564.txt.
Description
Fonny Cokro and seven colleagues follow patients with type 2 diabetes in Indonesia who were taking a modern class of glucose-lowering drugs, in this 2026 PLOS ONE real-world study. The drugs, which make the kidneys spill sugar into urine, have strong trial evidence behind them, but Indonesian patients differ from trial populations in diet, body type, and care access. Six hundred and thirty-eight patients across several centres were tracked for a year.
Those on the drugs improved in blood sugar control, weight, blood pressure, and cholesterol, and their calculated heart-attack risk fell. Compared with patients on other regimens, sugar and weight fell further. No major safety problems appeared. The authors read the results as reassurance that trial benefits survive contact with everyday Indonesian practice.
Catalog record
| CREATOR | Fonny Cokro, Rani Sauriasari, Dicky Levenus Tahapary, Heri Setiawan, Christian Tricaesario, Nurul Hidayati, William Djauhari, Jimmy Tandradynata |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34864 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |